Product Details
| Product Name:
BBIQ |
CAS No.:
1229024-57-0 |
| Purity:
99.71% |
Supply Ability:
10g |
| Release date:
2026/07/27 |
Product Introduction
Bioactivity
| Name | BBIQ |
| Description | BBIQ is a powerful vaccine adjuvant that enhances innate immune responses and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7. |
| In vitro | BBIQ induces IFN-α in human PBMCs (520 pg/mL at 5 µg/mL)[1]. |
| In vivo | In an experimental study, mice that received only Chloroquine (CQ) for treatment showed signs of the parasite (P. berghei ANKA) by Day 17 and succumbed by Day 21. Conversely, those administered a combination of BBIQ and CQ did not exhibit any parasitic presence up to Day 23. Additionally, the combined treatment with BBIQ + CQ resulted in a reduction of T cell frequencies (CD3+, CD4+, and CD8+) and T regulatory cell frequencies (CD4+, CD25+, and FoxP3+) in the brain when compared to the effects of BBIQ or CQ alone on Day 10. This treatment also elevated the serum levels of IFN-γ and IL-12, indicating a strong Th1 immune response against the infection on the same day. The study suggests that the BBIQ + CQ combination therapy not only inhibits the infiltration of inflammatory T cells but also activates T helper and T cytotoxic cells to combat the parasite effectively. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 3.31 mg/mL (10.02 mM), Sonication is recommended.
|
| Keywords | TLR7 | BBIQ |
| Inhibitors Related | Hydroxychloroquine | Benzyl alcohol | (±)-Naringenin | Chloroquine phosphate | Chloroquine | Chloranil | CU-115 | Thiamine hydrochloride | 2,4,5-Trimethoxybenzoic acid | Resiquimod | Stevioside | DHBP |
| Related Compound Libraries | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Bioactive Compound Library Plus | Antioxidant Compound Library | Immuno-Oncology Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$49.00
|
VIP7Y
|
TargetMol Chemicals Inc.
|
2026-07-27 |
United States